The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Dasatinib response in AML
Nathali Kaushansky, PhD, Weizmann Institute of Science, Rehovot, Israel, outlines the study which aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in leukemic stem cells. Results showed that dasatinib response in acute myeloid leukemia (AML) is correlated with FLT3/ITD, PTN11 mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
